Search filters

List of works by S Gail Eckhardt

A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer.

scientific article

A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer.

scientific article published on 23 August 2018

A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS

scientific article

A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer

scientific article

A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors

scientific article published in January 2008

A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy

scientific article

A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors.

scientific article published on 6 April 2010

An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function.

scientific article published on 22 September 2011

Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.

scientific article published on October 2015

Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program

scientific article published on September 2014

Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models.

scientific article

Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor Microenvironment

scientific article published on 01 January 2020

Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development.

scientific article

Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer

scientific article (publication date: 2014)

From bench to bedside: lessons learned in translating preclinical studies in cancer drug development

scientific article (publication date: 2 October 2013)

Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.

scientific article published on 05 October 2010

Is Precision Medicine an Oxymoron?

scientific article published on 01 February 2019

Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study

scientific article

Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer ⬇️

scientific article published on February 22, 2013

Novel agents in the treatment of metastatic colorectal cancer

scientific article published on May 2010

Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.

scientific article published on 17 September 2013

Patient-derived tumour xenografts as models for oncology drug development

scientific article

Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer ⬇️

scientific article published on February 14, 2012

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

scientific article

Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

scientific article

Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies

scientific article

Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers

scientific article published on 30 December 2015

Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer

Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib ⬇️

scientific article published on November 8, 2012

Results of a phase I trial of 12 patients with locally advanced pancreatic carcinoma combining gefitinib, paclitaxel, and 3-dimensional conformal radiation: report of toxicity and evaluation of circulating K-ras as a potential biomarker of response

scientific article published on 01 April 2009

The Insulin-like Growth Factor I Receptor/Insulin Receptor Tyrosine Kinase Inhibitor PQIP Exhibits Enhanced Antitumor Effects in Combination with Chemotherapy Against Colorectal Cancer Models ⬇️

scientific article published on October 13, 2010

Paulina is supported by:

About Paulina

Help